Orthocell CEO Reaches EY Entrepreneur Finals as ASX 200 Health Sector Advances

Highlights

• Paul Anderson, CEO of Orthocell Ltd (ASX:OCC, OTC:ORHHF), selected as finalist in EY Entrepreneur Of The Year Australia awards

• Orthocell strengthens commercial footprint with Remplir™ nerve repair device and global distribution deals

• ASX 200 healthcare segment sees momentum amid continued innovation and clinical development

Biotechnology company Orthocell Ltd (ASX:OCC), (OTC:ORHHF), a key player in the healthcare segment of the ASX 200, has garnered national recognition as CEO Paul Anderson was named a finalist in the 2025 EY Entrepreneur Of The Year Australia awards. This recognition highlights leadership within Australia’s advanced health technology space, with Orthocell contributing to the sector’s progression through innovation in regenerative medicine and surgical solutions.

The company, listed on both Australian and US markets, continues to expand its presence across global healthcare systems through its portfolio of medical devices aimed at nerve, tendon, and bone regeneration.

Leadership in Medical Technology Innovation

Paul Anderson, co-founder and current managing director of Orthocell, has been acknowledged in the Technology category of the EY awards. With a career rooted in both clinical practice and commercial operations, Anderson has guided Orthocell’s development from early research stages to global commercial activity. The awards, now in their milestone year in Australia, showcase leadership in developing scalable and impactful business models across diverse industries.

Orthocell’s core focus lies in translating regenerative medicine research into accessible surgical tools. Anderson’s leadership has helped the company move through regulatory pathways and expand into new markets, contributing to the broader evolution of the healthcare technology sector.

Remplir™ Accelerates Global Market Expansion

Orthocell’s lead product, Remplir™, is a collagen-based nerve repair device used by surgeons to restore function in peripheral nerve injuries. The product is designed for use in procedures involving the hands, face, and upper limbs. It is currently approved for clinical use in several countries, and the company continues to pursue additional regulatory approvals across key global jurisdictions.

A major step in expanding Remplir™’s footprint was marked by a distribution agreement with US-based Bioplate Inc. This agreement enhances market access in the United States, a leading region in advanced surgical care. Remplir™ is now positioned for increased availability in international healthcare systems, reinforcing Orthocell’s strategic goals in the nerve repair segment.

Striate+™ and SmrtGraft Advance Multi-Product Revenue Stream

Alongside Remplir™, Orthocell markets Striate+™, a dental membrane used in implant and bone graft procedures. The product continues to gain traction in several global regions, supported by a growing distribution network across North America, Europe, and Asia-Pacific.

Additionally, Orthocell’s tendon regeneration product, SmrtGraft, is in the final stages of approval processes in its home market. The device is designed for use in tendon repair procedures and complements the company’s wider regenerative medicine strategy.

These multiple products contribute to a diverse revenue base, which supports Orthocell’s clinical and commercial objectives across several continents.

Recognition Aligns With Company’s Commercial Milestones

The upcoming EY Entrepreneur Of The Year Australia awards gala is set to be held in Sydney. Finalists, including Orthocell’s CEO, represent a range of industries leading change and innovation across the country. Winners of the national competition will go on to participate in the global stage, engaging with peers from across more than sixty countries.

The recognition arrives during a period of growth for Orthocell as it continues to progress with international partnerships, product approvals, and broader clinical adoption of its technologies. The company’s achievements contribute to the momentum within the ASX 200 healthcare sector, driven by advancements in biotechnology and medical device innovation.